TheraQuest to Present Results of Intravenous Ketoprofen Postsurgical
Pain Study at the World Congress on Pain in Sydney
Blue Bell, PA – August 15, 2005 – PR
Newswire – TheraQuest Biosciences, a development stage pain management
company
today announced that it will present positive clinical trial results
for its injectable ketoprofen (TQ-1011) at the 11th World Congress
on Pain in Sydney, Australia on August 22, 2005.
TQ-1011 is a proprietary investigational injectable formulation
of the non-steroidal anti-inflammatory drug (NSAID) ketoprofen.
Injectable ketoprofen is being developed for the management of
moderate to severe postsurgical pain. TheraQuest has held regulatory
consultations with FDA, U.K. and Canadian authorities.
Najib Babul, PharmD, Chief Executive Officer of TheraQuest stated, "We
are excited about the positive results from this large, double
blind study in moderate to severe postsurgical pain. Intravenous
ketoprofen was superior to placebo and intravenous morphine on
the primary endpoint and on all secondary endpoints, including
onset of relief, peak relief, duration of relief, time to rescue
and patient global assessment of therapy.”
Babul added, “We believe injectable ketoprofen has significant
therapeutic and commercial potential for the treatment of postsurgical
pain. TheraQuest has filed a method of use and composition of matter
patent for ketoprofen and a number of other injectable NSAIDs,
including diclofenac and lornoxicam. The new formulations have
the potential to provide a more optimal efficacy and safety response
in patients with postsurgical pain.”
About TheraQuest
TheraQuest Biosciences, LLC is a private, development-stage pain
management company building a diversified portfolio of pharmaceutical
products to address a critical area of unmet medical need. Despite
their limitations, current treatments for acute and chronic pain
yield worldwide sales in excess of $25 billion. The TheraQuest
team has contributed to the development of numerous analgesics
approved in the U.S. over the past 20 years. TheraQuest’s
strategy is to use its expertise to identify, develop and commercialize
product candidates with strong market potential that have lower
development costs and reduced regulatory risk than new chemical
entities. TheraQuest is headquartered in Blue Bell, Pennsylvania.
TheraQuest is funded in part by BioAdvance, the Biotechnology
Greenhouse of Southeastern Pennsylvania and Ben Franklin Technology
Partners of Southeastern Pennsylvania. Additional information is
available at www.theraquestinc.com.
|
